Infections and anti–tumor necrosis factor α therapy

This publication has 43 references indexed in Scilit:

• Induction of Interleukin-12 and Gamma Interferon Requires Tumor Necrosis Factor Alpha for Protective T1-Cell-Mediated Immunity to PulmonaryCryptococcus neoformansInfection
  Infection and Immunity, 2002
• Tuberculosis and Treatment with Infliximab
  New England Journal of Medicine, 2002
• Effect of Deficiency of Tumor Necrosis Factor Alpha or Both of Its Receptors onStreptococcus pneumoniaeCentral Nervous System Infection and Peritonitis
  Infection and Immunity, 2001
• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy
  New England Journal of Medicine, 2001
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
  Cell, 1989
• Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study
  JNCI Journal of the National Cancer Institute, 1988
• Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
  Nature, 1987
• Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin
  Science, 1985